İbrahim C. Haznedaroğlu

The effects of blood group types on the risk of COVID-19 infection and its clinical outcome

Hakan Göker, Elifcan Aladağ, Halûk Demiroğlu et al. · TURKISH JOURNAL OF MEDICAL SCIENCES · 2020 · 206 citations · Full text

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti et al. · Blood · 2009 · 196 citations

Global Fibrinolytic Capacity Is Decreased in Polycystic Ovary Syndrome, Suggesting a Prothrombotic State

İbrahim C. Haznedaroğlu, Şerafettin Kirazlı, Miyase Bayraktar · The Journal of Clinical Endocrinology & Metabolism · 2002 · 134 citations · Full text

Fertility, Reproductive Health, Gynecology +24

Cytokines in Behçet's disease.

O I Ozcebe, Ö Özdemir, İbrahim C. Haznedaroğlu et al. · PubMed · 1996 · 132 citations

Evaluation of hemostatic effects of Ankaferd as an alternative medicine.

Yavuz Beyazıt, Mevlüt Kurt, Murat Kekilli et al. · PubMed · 2010 · 98 citations

Translational Medicine, Ankaferd Blood Stopper, Alternative Medicine +15